...so putting the two posts together: slides 30 - 35 are all new and they all refer to work on lysosomal storage (Kayaker); but there is no new data concerning lysosomal research (BDAZ).  So, why highlight them in this new presentation (smoke/fire)? 

Traction for BTI will come from xB3 001 when it gets into the clinic - Phase 1b.  To get there we need some funding, driven by either new data, which drives another licencing deal, or funding from an existing deal which may produce a milestone payment.  We don't know the structure of the Chiesi deal, but maybe we're close to a possible milestone payment associated with that deal - which may explain why the lysosomal storage research was featured in the latest presentation.